About a third of lung transplant patients with cystic fibrosis receive elexacaftor-tezacaftor-ivacaftor; use is higher among ...

Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients ...

The guidance updates a list of conditions that disqualify potential recruits from serving in the armed forces.

The Pentagon has issued new rules that would prevent people currently treated for schizophrenia, congestive heart failure, ...

Vertex Pharmaceuticals (VRTX) announced that Health Canada has granted Marketing Authorization for ALYFTREK, a new triple combination therapy for ...

For the 300,000 Americans living with the immune disease scleroderma, better treatments can't come soon enough. The rare and ...